Patent · US Active

Anti-TEM1 antibodies and antigen-binding portions thereof

US12297276B2 · kind B2 · utility

0Cited by

0References

32Claims

0Family size

Assignees

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.) · CH
Universite de Lausanne · CH

Inventors

Steven Mark Dunn · Abingdon, GB
Julie K. Fierle · Épalinges, CH
George Coukos · Lansdowne, US

Key dates

Filing date	May 29, 2020
Grant date	May 13, 2025
Priority date	—
Expiry date	Aug 12, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.